Loading...
Loading...
Arrowhead Research Corporation
, a targeted therapeutics
company, today announced that it has received a Notice of Allowance from the
U.S. Patent and Trademark Office for U.S. Patent Application Number 13/336,028
entitled, “In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive
Linkages.” This new IP expands the Dynamic Polyconjugate (DPC) platform,
broadly protecting Arrowhead's next generation DPC polymer masking
technology. Using this masking technology, DPCs can be engineered for long
circulation times and improved tissue-targeting characteristics. In addition,
hepatocyte-targeted DPCs formulated using this new masking technology have
shown to be highly potent upon subcutaneous administration. The company has
previously reported target gene knockdown of 99% in monkeys after a single
subcutaneous injection of 1 mg/kg, with >80% knockdown for 3 months.
Additional data will be reported at upcoming scientific conferences and
through peer-reviewed publications.
“This patent protects a new masking chemistry that broadens the reach of
DPC-enabled RNAi therapeutics. It enables efficient subcutaneous delivery of
siRNA and opens up new therapeutic area targets including oncology,” said Dr.
Chris Anzalone, President and CEO of Arrowhead. “Arrowhead scientists continue
to discover innovative solutions for siRNA delivery and we look forward to
providing updates on how these technologies are being deployed to create new
drug candidates.”
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in